Navigation Links
Morria Biopharmaceuticals Plc Announces Results From its Pre-Clinical Screening of Novel Anti-Inflammatory Compounds
Date:10/7/2008

LONDON, Oct. 7 /PRNewswire/ -- Morria Biopharmaceuticals Plc, a biopharmaceutical company focused on the development of novel anti-inflammatory drugs, announced today the results of the ongoing screening of its novel anti-inflammatory drugs using MD Biosciences' Immunoprofiler(TM) in vitro screening service. The screen was specifically chosen to identify and assess the anti-inflammatory properties of Morria's proprietary multi-functional anti-inflammatory compounds. The Immunoprofiler(TM) Screen uses rat macrophage cells which are stimulated using endotoxin (LPS), a potent inflammation-inducing agent. The assay measures key inflammatory mediators, which are released by the stimulated cells. A steroid comparator is included as a positive control.

Morria's lead compounds significantly reduced the levels of the following inflammatory mediators: GM-CSF (Granulocyte Macrophage Colony-Stimulating Factor), IL-1 beta, IL-6, TNF-alpha (Tumor Necrosis Factor alpha), MIP-1 alpha (Macrophage Inflammatory Protein 1 alpha), MCP-1 (Monocyte Chemoattractant Protein-1), IP-10 (Inducible Protein 10) and PGE-2 (Prostaglandin E-2). Cell proliferation assay (XTT reduction) demonstrated that these effects were not caused by cytotoxicity. The anti-inflammatory efficacy was comparable or better than the steroid control in each case.

"We are pleased by the wide range of divergent inflammatory mediators that we are modulating, several of which have been extensively covered in the scientific literature recently. Mediators, such as IL-6, IL-8 and TNF-alpha, are currently targets of research and development in the pharmaceutical field, and our synthetic compounds clearly modulate them efficiently," said Yuval Cohen, President of Morria Biopharmaceuticals.

Specifically, several of the inflammatory mediators assayed have been identified as important players in Morria's current clinical programs (allergic rhinitis and dermatitis) and pre-clinical programs (asthma, Inflammatory bowel disease [IBD], ophthalmology and cystic fibrosis) and also offer insights into potentially new pharmaceutical applications.

ABOUT MORRIA BIOPHARMACEUTICALS Plc

Morria Biopharmaceuticals Plc is a biopharmaceutical company focused on the development of novel anti-inflammatory pharmaceuticals termed multi-functional anti-inflammatory drugs (MFAIDs). This class of drugs uniquely combines two promising approaches to preventing and reversing inflammation: first, they control the phospholipase A2 (PLA2) enzyme family, a known, but previously elusive anti-inflammatory drug target. At the same time, they also protect cells and tissues against inflammatory damage. Morria is determined to become a pivotal player in the $20 billion anti-inflammatory drug market by developing and commercializing novel drugs for acute pulmonary and gastro-intestinal inflammatory diseases. For more information, please visit http://www.morria.com .

This is not an invitation nor is it an offer to purchase or subscribe for shares. This release is only intended for persons falling within the exception set out in regulation 47 of the Financial Promotion order -- Persons in the business of disseminating information.

Contacts:

Richard Lewis Communications, Inc.

212-827-0020

Cecelia Heer, Investors

cheer@rlcinc.com

Timothy Rathschmidt, Media

trathschmidt@rlcinc.com


'/>"/>
SOURCE Morria Biopharmaceuticals Plc
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Morria Biopharmaceuticals Plc Appoints Dr. Johnson Lau and Dr. David Sidransky to Board of Directors
2. Morria Biopharmaceuticals Plc Announces Appointment of Dr. Rosemary Mazanet as Interim Chief Executive Officer
3. Nomad Bioscience: New Plant Biotechnology Company Founded to Focus on Biomaterials and Biopharmaceuticals
4. Bayer Broadens Its Manufacturing Basis for Biopharmaceuticals in Tobacco Plants
5. XTL Biopharmaceuticals Receives Notice of Non-Compliance with Nasdaq Marketplace Rule Due to Changes in Board Composition
6. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
7. Keryx Biopharmaceuticals to Present at the Jefferies & Co. Healthcare Conference
8. XTL Biopharmaceuticals Announces Appointment of Laurence N. Charney to Board of Directors
9. XTL Biopharmaceuticals to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
10. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2008 Financial Results
11. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on First Quarter 2008 Financial Results on Monday, May 12, at 8:30 A.M. EDT
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... 27, 2016  Global demand for enzymes is ... 2020 to $7.2 billion.  This market includes enzymes ... products, biofuel production, animal feed, and other markets) ... biocatalysts). Food and beverages will remain the largest ... consumption of products containing enzymes in developing regions.  ...
(Date:6/27/2016)... ... June 27, 2016 , ... Cancer experts from ... believe could be a new and helpful biomarker for malignant pleural mesothelioma. Surviving ... to read it now. , Biomarkers are components in the blood, tissue ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... will join the faculty of the University of North Carolina Kenan-Flagler Business ... strategy and entrepreneurship at UNC Kenan-Flagler, with a focus on the school’s international ...
(Date:6/24/2016)... 24, 2016  Regular discussions on a range of subjects ... the two entities said Poloz. Speaking at a ... , he pointed to the country,s inflation target, which ... "In certain areas ... have common economic goals, why not sit down and address ...
Breaking Biology Technology:
(Date:5/3/2016)... , May 3, 2016  Neurotechnology, a ... the MegaMatcher Automated Biometric Identification System (ABIS) ... large-scale multi-biometric projects. MegaMatcher ABIS can process multiple ... using any combination of fingerprint, face or iris ... MegaMatcher SDK and MegaMatcher Accelerator , ...
(Date:4/28/2016)... 2016 First quarter 2016:   ... with the first quarter of 2015 The gross margin ... (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... unchanged, SEK 7,000-8,500 M. The operating margin for 2016 ...
(Date:4/26/2016)... 27, 2016 Research and ... Biometrics Market 2016-2020"  report to their offering.  , ... The analysts forecast the global multimodal biometrics ... during the period 2016-2020.  Multimodal biometrics ... such as the healthcare, BFSI, transportation, automotive, and ...
Breaking Biology News(10 mins):